NO970685L - Mounting device for a sanitary element - Google Patents

Abstract

The arrangement consists of a shallow box (4) which is mounted with its open end against a wall using four mounting lugs (14). The face of the box has a pattern of holes (20,21) on which any one of a variety of sanitary fixtures can be mounted. The arrangement further incorporates an accessory box (36), for e.g. valves, which has an extension (38) with which it fits into an opening in the top side of the box. The extension has a row of teeth (42,43) along either side with which securing elements (44,45) can be made to engage and which allow the vertical position of the accessory to be adjusted.

Description

The invention relates to a fastening device for a sanitary element, in particular a urinal, according to claim 1.

From DE 8 902 318 such a fastening device is known which is designed as a frame structure, preferably for mounting in front of a wall. The fastening device is made up of vertical beams and traverses which are produced separately and which are connected to each other by means of screws etc. The manufacturing effort is not insignificant.

Furthermore, DE 2 249 788 discloses a sanitary cell with a U-shaped panel to cover the inlet and outlet pipes of a ser-vant. This panel is formed in one piece as a support for branch pipes, connecting and connecting joints for the basin and towards the floor provided with support feet. The weight of this panel rests essentially on the support feet against the floor. In the interior of the panel, in a plane above the washbasin, there is a stationary, preferably equipped with a holding device connected to a wall in the room, which is designed as a bent U-shaped rail. On the upper side and on the lower side, the panel is shaped open and on the side there are two arms that extend the entire length of the panel, which essentially run at right angles to the front wall of the panel. The panel essentially extends the entire height of the room and thus serves as a cover for water pipes and drain pipes which are placed on the wall of the room and which extend the entire height of the building through the floors. This sanitary cell is a rather large and bulky device, the handling and assembly of which requires a considerable amount of effort.

With this starting point, the task underlying the invention is to create a compact and at the same time universally applicable fastening device. The fastening device must require little manufacturing and assembly effort and the adaptation to differently designed sanitary elements, such as urinals in particular, must be achievable in a simple way and functionally reliable. The fastening device must have little weight and still have a high stability and a long service life, and a high level of functional safety must be ensured.

The solution to this task appears in requirement 1.

The fastening device that is proposed contains a box-shaped basic body which has several holders or openings in its front wall. These holders or openings are adapted to the hole distances of threaded bolts or other connection elements for sanitary fittings. The basic body is appropriately designed in one piece, so that labor-intensive manufacturing processes and the joining of different individual parts are eliminated. In a special design, the basic body is made of plastic. preferably produced in a spray process. Due to the plastic-only design of both the base body and the connecting parts that will be described in the following and occasionally a pipe clamp for the drain pipe will prevent corrosion problems, which in practice occur with profile rails and the like made of metals, for example in cavities behind covers, and a long service life for decades is secured. In addition to the essentially flat front wall and the two side walls, the base body contains an upper wall above, where the stability of the base body is considerably improved with the connection created between the two side walls through the upper wall. Preferably, the front wall is shaped flat. Appropriately, there are walls on the underside which are also directed backwards, so that there is at least approximately a closed frame around the whole. The basic body, which is thus designed in one part, has, with little material input and finally with little weight, a high stability and ensures a functional attachment for differently designed sanitary elements.

Furthermore, as far as the invention is concerned, a connection unit which can be adjusted in height is placed at the upper end of the base body. This connection unit contains, for operating the water flushing of the sanitary element, in particular a supply unit, valves, a flush pipe arc or the like, in order to be able to supply the sanitary element with flushing water as needed. The connection unit is thus designed as a holding body for the aforementioned components, which for the most part are pre-assembled in the workshop, so that on the construction site the on-site assembly effort is significantly reduced. Due to the arrangement of the connection unit, which can be adjusted in height, adaptation to different installation conditions and/or differently designed sanitary elements can be carried out with minimal effort. Special fastening elements for valves, pipelines or the like for the flushing water on the brick wall or on the structure in front of the wall are omitted.

The connection unit is preferably designed so that its leading edge lies substantially in the same plane as the front of the surface of the front wall of the base body. After the mounting of the fastening device, the base body as well as the connection unit is covered with tiles, plates or the like, whereby the opening at the front of the connection unit remains open, so that the valves and the like that are provided inside the connection unit are easily accessible at all times. Most expediently, the leading edge can protrude in front of the mentioned plane to the surface, how much is indicated in advance, and so that it is of the order of magnitude of the thickness of the tiles and/or cover plate, or of the order of magnitude from 10 to 20 mm. The connection unit preferably contains a box and an adjustment rail for which guide means are appropriately provided behind the front wall of the base body. These guide means can preferably have an opening in the upper transverse wall of the base body and or guide rails which are placed behind the front wall.

The connection unit is designed to be open on the front, so that even when assembled, pipes, valves and the like that are inside the holding body are easily accessible. After assembly, this opening on the front side of the holding body is covered with a cover plate which also contains a push button, sensor or the like to trigger a flushing sequence.

In the area at the lower end of the front wall, there is a recess for a pipe clamp that serves to attach the drain pipe to the sanitary system. This pipe clamp is placed adjustable in height and can thus be adapted to different installation and installation conditions. The walls of the recess have grooves for corresponding chambers on the pipe clamp, where these grooves and chambers are preferably placed horizontally. The pipe clamp is thus simply pushed in from the front at the desired height and locked in the recess. No special tool is required to arrange the pipe clamp and a small installation effort is ensured. In this context, it should also be noted that the described upper connection unit is likewise positioned without special tools by inserting fastening elements into corresponding grooves and/or chambers and/or a rack with simple handles at the desired height in relation to the base body.

Special designs and further developments of the invention are specified in the subclaims and are explained further in the description.

The drawing shows special design examples for the fastening device which relates to the invention. Figure 1 shows here

a perspective sketch of the fastening device, figure 2 shows the holding body, figure 3 shows the pipe clamp which is designed in two parts, figure 4 shows a mounting angle, figure 5 a representation in perspective of a realized design example for the fastening device which relates to the invention.

Figure 1 shows in a perspective representation from the front the fastening device with a box-shaped basic body 2. The basic body 2 has an essentially flat and/or flat front wall 4

and also side walls placed vertically parallel to each other in a built-in situation, of which here only one side wall 6 can be seen. The side wall 6 has a recess 8 with an opening to the rear where a fitter can intervene with his hand. Both side walls have such recesses, so that handling during installation and assembly is significantly simplified. Furthermore, pipes, wires, carriers and the like can lie in the area of the recesses, so that the installation of the basic body is thus advantageously not hindered.

At the upper end, the base body 4 has an upper transverse wall 10 and corresponding transverse walls are also provided on the underside. With these walls placed around all sides and connected to each other, forming a frame, a high stability is achieved with little weight. The basic body is open to the rear and for bracing, bracing ribs are provided between the front wall and the sides and cross walls. In the side wall 6 and likewise in the other side wall there are slits 12 which enable connection to a mounting angle 14 by means of screws or similar fastening elements. The rear arm 16 according to the drawing serves for attachment to a building wall or with a frame system for mounting in front of the wall. With the here vertical slot 12 and as needed with several slots or bores 18 in addition in the side wall, the connection of a frame construction to a mounting system also takes place immediately in front of the wall.

In the front wall 4, there are some openings 20, 21 placed symmetrically to a longitudinal plane 22. To attach a sanitary element, especially a urinal, a left opening 20 and a right opening 21 are needed on each side for the passage of a threaded bolt or the like . The various openings 20, 21 are positioned so that most common sanitary elements can be connected to the base body 2.

At the lower end, the base body has a recess 24 for a pipe clamp 26. The walls 28 on the sides of the recess have horizontally aligned grooves 30 with which the chamber 32 of the pipe clamp 26 can be brought into engagement. Consequently, the pipe clamp 26 can be pulled out in a horizontal direction forwards out of the recess 24 and inserted in the opposite direction. The grooves 30, which are placed one above the other at distances that can be specified in advance, enable a simple adjustment of the pipe clamp 26 in the horizontal plane 22 or the vertical height. As will be explained below, the pipe clamp can be handled from the front in order to fix the drain pipe. The installation and fastening of the drain pipe thus takes place with very little effort.

At the upper end of the base body 2, a holding unit 34 is placed which can be adjusted in height in relation to the base body 2. The holding unit 34 contains an open box 36 open at the front to hold valves, operating elements or the like, in order to supply the sanitary element, especially urinal flush water. On the underside of the box 36 with a front edge 37, an adjustment rail 38 is connected which is guided in the guide means 39 in the base body 2. The guide means 39 in particular contains an opening 40 in the upper transverse wall 10 in the base body 2 and/or guide strips 41 or the like on the back of the base body 2, preferably on its front wall 4. The holding unit 34 can thus be positioned at a height in relation to the base body 2, so that the box 36 has a defined distance to the base body 2, preferably to the described opening or the attachment points 20, 21 and finally to the sanitary element which is fixed there. The adjustment rail 38 protrudes through the opening 40 in the upper transverse wall 10 into the open space behind the front wall 4. The adjustment rail has on the outside a rack 42, 43, whereby after vertical adjustment of the entire holding unit 34 it can be fixed to the base body 2. This serves the fastening elements 44, 45 which, with parts not visible here located behind the front wall 4, engage in the racks 42, 43. For positioning the holding unit, the fastening elements 44, 45 must only be moved forwards out of the front wall 4, so that they no longer engage with the rack 42, 43. No special tools are required to adjust the holding unit, but the fastening elements 44, 45 must only be released in the manner described or brought back into engagement with the racks 42, 43.

In the adjustment rail 38, a flush pipe 46 is also placed, where the upper mouth 48 can be seen in the interior of the box 36. At the lower end of the flush pipe 46, a connection 50 for the inlet to the sanitary element is provided. The length of the flush pipe 46 is specified in advance in accordance with the requirements and thus the distance to the connection 50 to the box is varied. This ensures a high level of flexibility during assembly. The front wall 4 appropriately contains a slot 52 which extends downwards, where the connecting body 50 can be suitably moved and positioned.

The foremost surface of the front wall 4 lies in a plane which, with the fastening device in the assembled state, is essentially aligned vertically. As far as the invention is concerned, the holding unit 34 is positioned so that it is substantially behind the mentioned plane. As can be seen, the adjustment rail 38 satisfies this condition, because it is, as far as the invention is concerned, located behind the front wall 4. Also the box 36 is mostly located behind the mentioned plane which is formed by the surface of the front front wall. With the design shown here, only the front edge 37 protrudes a predetermined distance in front of the said plane. As is well known, the walls in toilets and washrooms are fitted with cladding, particularly with tiles. The mentioned distance therefore corresponds to the usual thickness of such cladding and/or the mentioned tiles.

Figure 2 shows an enlarged view of a holding unit 34 with the box 36 and the adjustment rail 38. The pipe connection 50 is at the lower end of the flush pipe 46 and corresponding to the length of the flush pipe 46, the distance 54 to the pipe connection 50 to the box 36 can be specified in advance. Correspondingly, the distance for the connection to the upper edge of the base body in relation to the positioning of the holding element 34 with regard to the base body 2 is also of course specified in advance. As already described, the fixing of the holding unit 34 in the base body takes place with the toothed bars 42, 43 which are placed on the side of each of the adjustment rails 38. That is to say that within the scope of the invention, the positioning and fixing can be done in addition to the particularly suitable toothed bars shown here also after needs are realized in a comparable way with latching elements, snap connections or the like.

In Figure 3, the pipe clamp 26 which relates to the invention is shown enlarged, it is designed in one piece and contains a yielding movable lower part 54. Here also the already mentioned combs 32 on the side of the pipe clamp 26 for engagement in the assigned grooves in the recess to the basic body is clearly visible. Pipe clamp 26

contains an upper part 56 shaped like a bridge and ribs 60 standing to the inner wall 58. The lower part 54, on the other hand, is designed to be relatively bendable and flexible, so that it can be placed around the outer surface of a pipe. By means of a screw 62 which can be screwed into corresponding threads in the lower part 54, the tube is clamped. It is of particular importance that the screw 62 in relation to the vertical line 64 is placed at an angle 66 which is such that the screw head is accessible on the front side obliquely from above. In this way, a cumbersome manipulation on the back of the sanitary element for fixing the connection pipe is avoided in a particularly convenient way.

Figure 4 shows the mounting angle 14 with its horizontal slots 68, 69 for the already mentioned fastening elements. For stiffening and to achieve a low material consumption, the mounting angle 14 has ribs 70 which appropriately extend in the longitudinal direction. The mounting angle 14 suitably consists of plastic. Furthermore, it is expressly stated that the basic body 2 and likewise the pipe clamp 26 and the holding unit 34 consist of plastic. With this design made only of plastic, difficulties with corrosion are avoided and a long service life for the fastening device relating to the invention is ensured. The fastening device is advantageously shaped as a raw construction module and designed for wet construction, installation in a niche, installation between double studs and/or in combination with light construction cladding.

In Figure 5, a special design of the fastening device is shown, where the base body 2 on the front wall 4 has markings 72 in the form of numbers which are assigned to the different openings 20 and 21. With these markings 72, the correct mounting and insertion of suitable threaded bolts and the like for every sanitary element simplified. On the pipe clamp 26, markings 74 have been assigned to the side of the lowest recess 24, which likewise facilitate the correct insertion of the pipe clamp 26. Finally, the adjustment rail 38 is also provided with markings 76 which ensure a correct positioning adapted to the sanitary element. In the interior of the box 36, studs 78 can also be seen for attaching a valve or the like. Furthermore, a partition wall 80 is provided inside the box which serves as electrical insulation between water-conducting parts and the electrical connections, for example an electromagnet valve. Finally, in the corner areas there are holds 82 for screws which make the boxes 36, which are open at the front, lockable after the assembly and completion of the installation work.

With this particular design, the box 36 contains in the area at the front edge 37 a frame or flange 84. The front side of the flange 84 visible here lies essentially in the same plane as the leading surface 86 of the front wall 4. At the upper end of the front wall, this a recess 88, where the flange 84 rests with its lower end when the holding unit 34 is pushed all the way down. The box 36 also has openings 90, 92 on the side, through which cables, whether electrical cables or water lines, can be passed through. A connection of the mentioned wires on the sides is thus possible without problems and a small installation depth can be easily realized without special angle pieces, arches or the like.

Claims (22)

1. Fastening device for a sanitary element, in particular a urinal, which contains a front wall (4) with openings (20, 21) or holders for connecting elements for the sanitary element, CHARACTERIZED IN THAT the front wall (4) is designed as a component of a basic body (2) and has the openings (20, 21) or the holders and that a holding unit (34) is placed at the upper end of the base body (2) which can be adjusted in height. 2. Device according to the preceding claim, CHARACTERIZED BY the fact that from the front wall (4) there are side walls (6) which protrude backwards, essentially positioned parallel to each other, which have open recesses (8), preferably towards the back and/or that in the upper end of the front wall (4) is placed a transverse wall (10) which is directed backwards. 3. Device according to the preceding claim, CHARACTERIZED IN THAT the basic body (2) is box-shaped and/or formed in one part and/or consists of plastic and/or has a recess (24) at its lower end to hold a pipe clamp (26) . 4. Device according to the preceding claim, CHARACTERIZED IN that the holding unit (34) is essentially located behind a plane where the leading surface (86) of the front wall (4) is located and/or that the holding unit (34) has a box at the upper end (36) and an adjustment rail (38) running downwards from this as a connection with the base body (2) and/or that the adjustment rail (38) is located behind the front wall (4) and/or that the base body (2) contains guide means (39-41) ) for the adjustment rail (38). 5. Device according to claim 4, CHARACTERIZED IN THAT the guide means on the back of the front wall (4) contain at least one guide strip (41) and/or an opening (40) specially placed in the upper transverse wall (10), where the adjustment rail (38) passes through the opening (40) and/or at least partially rests against the guide strip (41). 6. Device according to claims 3-5, CHARACTERIZED IN THAT the pipe clamp (26) is placed in the recess (24) vertically positionable in relation to a vertical longitudinal plane (22). 7. Device according to claims 3-6, CHARACTERIZED IN THAT the pipe clamp (26) can be placed inside the recess (24) from the front in a horizontal direction and/or that the recess (24), preferably in the walls (24) on the side, has several grooves, as in vertical direction are at a certain distance from each other and where the corresponding chamber (32) on the pipe clamp (26) engages. 8. Device according to claims 3-7, CHARACTERIZED IN THAT the pipe clamp (26) has an upper bridge-like part (56) and in relation to this has a flexibly positioned lower part (54), where the connection between lower part (54) and upper part (56) takes place using a screw (62) which can preferably be screwed in at an angle from above from the front. 9. Device according to preceding claim, CHARACTERIZED IN THAT the holding unit (34), preferably its adjustment rail (38) has a rack (42, 43) and/or that a fastening element (44, 45) can be brought into engagement with both the base body (2) as also with the adjustment rail (38), especially the rack (42, 43) and/or that the holding body (34) has a flush tube (46) with a connecting body (50) and/or that the connecting element (50) has a distance (54) which can be set to the box (36) of the holding body (34). 10. Device according to the preceding claim, CHARACTERIZED IN THAT the base body (2), especially its front wall (4) has a downwardly directed slit (52) that extends from the upper edge, where the connection body (50) can be moved along this when adjusting the holding body (34) . ANTI-ARRYTHMIC AGENTS The present invention relates to new substituted co [phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl] [alkyl, alkenyl or alkynyl] amine carboxamides, sulfonamides and phosphonylamides which are useful as anti-arrhythmic agents. Anti-arrhythmic agents are classified into one of four categories, sodium channel blockers (class I), calcium channel blockers (class II), potassium channel blockers (class III) and β-adrenergic blockers (class VI) based on their ability to exhibit clearly definable pharmacological effects. The compounds of the present invention produce a homogeneous prolongation of repolarization and resistance indicative of class III anti-arrhythmic activity. The electrophysical mechanism underlying the prolongation of repolarization is known to be the blocking of currents through the heart's potassium channels. Class I antiarrhythmic agents, however, mediate their pharmacological effect through sodium channel blockade. In Purkinje fibers and papillary muscle preparations from dogs, the class III antiarrhythmic effect of quinidine is manifested by the prolongation of action potential duration (APD). The prolongation of the APD and the effective refractory period (ERP) has also been shown with other class III antiarrhythmic agents such as d-sotalol (N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl ]phenyl]methanesulfonamide, dofetilide (4'-(2-[methyl[4-methylsulfonylamino)phenethyl]amino]ethoxy)methanesulfonanilide and E-4031 (1-[2-(2-methylpyridin-6-yl)ethyl]-4 -(4-methanesulfonylamino-benzoyl)piperidine) which have shown pharmacological effects in clinical studies.The increase in APD in cardiac muscle has thus become an in vitro standard measure for putative class III antiarrhythmic agents. Class III anti-arrhythmic activity has been established as a viable therapeutic strategy for monitoring ventricular arrhythmia and preventing sudden cardiac death. Some later reviews of Class III agents include: Gibson and Kersten, Drug Dev. Res., 1990, 19: 173-185; Carmelite, Fundam. Clin. Pharmacol. 1993, 7, 19-28; Harrison and Bottorf, Advances in Pharmacology, 1992, 23: 179-215; Crimini and Gibson, Ann. Reports in Medicinal Chem. 1992, 27: 89-98. Racemic sotalol is a structural prototype of anti-arrhythmic drug with a pharmacological activity derived from blocking the delayed rectifier subclass of potassium channels. Sotalol is a phenethanolamine derivative containing a methylsulfonamide group. Structural variations of this compound in which either chain extension at carbon or oxygen atoms or addition of a 2nd aryl group such as 4-phenoxyimidazole have been achieved. However, the presence of a basic amine group in the original phenethyl chain has been retained. A general pharmacophore model for this class of compounds has been defined, and a generalized structure has been proposed (Prog. Med. Chem.1992, 29, 65) which ties together the structural variations; where Q is an electron-withdrawing group, A is a bond of one to four atoms between the aryl group and the nitrogen atom and R, and the R2 substituents are selected from hydrogen, alkyl, arylalkyl or heteroarylalkyl groups. The present invention is a deviation from the general structure I, in that a carbonyl, sulfonyl or phosphoryl group is bound to the nitrogen (NH) atom. The present substituents change the physico-chemical properties of the nitrogen atom and therefore the pharmacophore from one that is basic as in structure I to one that has either neutral or acidic properties. This new departure from the general pharmacophore defines a series of compounds that have significant activity in the action potential prolongation procedure indicative of anti-arrhythmic activity. Summary of the invention This invention relates to new derivatives selected from those of the general formula I: in which R1 is R<3> is C1-C3 straight chain alkyl; X is O, S, SO or SO 2 ; There ner an integer from 3 to 10; k is an integer from 1 to 4; m is an integer from 1 to 4; Yer R <2> is or Cr C8 alkyl, straight chain or branched Z, Z <1> and Z <2> are independently selected from H, CVC4 straight chain or branched alkyl, -CF3 , -NO 2 , -NHCOR <3> , -OR <4> , -CN, Cl, Br, F or I; R 4 is C 1 -C 4 straight or branched alkyl; and A is oxygen or a bond or a pharmaceutically acceptable salt thereof. A pharmaceutically acceptable salt is an addition salt formed between a compound of the invention with a basic nitrogen and a pharmaceutically acceptable acid such as one of the inorganic acids hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid, or an organic acid such as acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid , succinic acid, methanesulfonic acid or benzoic acid. Within the group of compounds defined by formula I, the most preferred ones compounds be those in which R <1> is X is O and Y is SO 2 R <2> . Detailed description of the invention The new compounds according to the present invention can be easily prepared according to the following reaction scheme. Unless otherwise stated, all variable values must be as previously defined. The compounds of formula I wherein D is -(CH2 )n - can be prepared as described in scheme I by dissolving a base such as sodium methoxide in a lower alkanol solvent and adding 1, or dissolving 1_in N,N-dimethylformamide and treating with sodium hydride to form of 2. Reaction of 2 with the 2-(co-bromoalkyl) derivative of 1H-isoindole-1,3(2H)-dione 3 in a lower alkanol solvent followed by stirring at from room temperature to the reflux temperature of the solvent for 12 to 16 hours affords the intermediate 4. The product is isolated by cooling, collecting the solid, washing the solid with water and drying. Alternatively, reaction of 2 with 3 in N,N-dimethylformamide at or between room temperature and 95°C on a steam bath in 4, which is isolated by dilution with five to ten volumes of water and collection of the product by filtration or by evaporation of N,N -the dimethylformamide at reduced pressure and collection of the residue by filtration. Conversion of 4 to the free amine 6 or amine salts 5 is carried out by dissolving or suspending 4 in refluxing ethanol containing either hydrazine or monomethylamine for 12 to 18 hours, cooling and collecting the insoluble precipitate. The precipitate is washed with two to five equivalents of 1 N HCl and the filtrate is saved. The ethanol filtrate is concentrated to dryness, and the residue is slurried in 1 N aqueous HCI solution. The insoluble matter is removed by filtration. The combined 1 N HCI solutions are evaporated to form the HCI salt 5. Alternatively, the filtrate can be made alkaline with NaOH, cooled to 0°C and the free base 6 collected by filtration. In addition, reaction of 2 with 7 where n is 3 to 10 using conditions similar to those used in the reaction of 2 and 3 will yield 8. Reduction of 8 using either hydrogen and a metal catalyst such as 10% palladium on carbon or a complex metal hydride such as lithium aluminum hydride when isolated gives 6. The hydrochloride salt 5 is added to water and 2.5 equivalents of sodium hydroxide are added. Sulfonyl chloride 9 where Y is -SO2 R <2> is dissolved in an ether solvent such as diethyl ether and added dropwise to 6. After stirring for two to 16 hours the precipitate is collected, washed with water and ether, dried and crystallized to give 10, where Y is -SO 2 R 2 . Alternatively, 6 is dissolved in pyridine and a slight molar excess of 9 is added where Y is -SO 2 R 2 . The reaction mixture is stirred at between room temperature and steam bath temperature for eight to 16 hours. The pyridine is removed under reduced pressure and the residue is washed with water, dried and crystallized to form 10. Also, 6 is dissolved in dichloromethane containing an excess of triethylamine or N,N-diisopropylethylamine followed by addition of 9 where Y is -SO 2 R <2> . The reaction mixture is stirred at or between room temperature and the reflux temperature of the solvent for two to 18 hours. The solvent is concentrated under reduced pressure and the residue is washed with water, dried and crystallized to give 10 where Y is -SO 2 R 2 . In addition, 5 or 6 is traded with 9 where Y is and to form 10 using the conditions for the preparation of 10 where Y is -SO 2 R 2 . Furthermore, 5 or 6 is converted to 9 where Y is and A is oxygen or a bond to form 10 using the conditions described for the preparation of 10 where Y is -SO 2 R 2 . Oxidation of 10 wherein X is S with one equivalent of an aryl or alkyl carboxylic peracid produces the sulfoxide Ha or the sulfone Hb when an excess of the oxidizing reagent is present. The compounds of formula I wherein D is is prepared as described in scheme II by reacting the olefins 12a and 12b in which W is Br or Cl with potassium salts of 1H-isoindole-1,3(2H)-dione in N,N-dimethylformamide at or between room temperature and the reflux temperature of the solvent in 12 to 16 hours during the formation of the intermediates 1_3a and 13b. Treatment of 13c with sodium hydride or sodium methoxide in N,N-dimethylformamide followed by reaction with 13a and 13b gives 14a and 14b. Reaction of 14a and 14b with hydrazine or monomethylamine in refluxing ethanol gives the free amines 1_5a and 1_5b or the acid addition salts such as hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate or sulfate 15c and 15d. Sulfonyl chloride 9 where Y is -SO2 R <2> is dissolved in an ether solvent such as diethyl ether and added dropwise to 15a and 15b. After stirring for two to 16 hours, the precipitate is collected, washed with water, ether, dried and crystallized to give 16a and 16b, where Y is -SO 2 R <2> . Alternatively, 1_5c and 15d are dissolved in pyridine and a slight molar excess of 9 is added where Y is -SO2 R <2> . The reaction mixture is stirred at or between room temperature and the reflux temperature of the solvent for eight to 16 hours. The pyridine is removed under reduced pressure, and the residue is washed with water, dried and crystallized to form 16a and 16b. Also, 15c and 1_5d are dissolved in dichloromethane containing an excess of triethylamine or N,N-diisopropylethylamine followed by addition of 9 where Y is -S02 R <2> . The reaction mixture is stirred at or between room temperature and the reflux temperature of the solvent for two to 18 hours. The solvent is concentrated under reduced pressure and the residue is washed with water, dried and crystallized to form 16a and 16b where Y is -SO 2 R 2 . In addition, 15a, 15b, 15c or 15d are reacted with 9 where Y is and R<2> is as defined herein previously during the formation of 16a and 16b using the conditions for the preparation of 10 where Y is -SO 2 R<2> . Furthermore, 15a, 15b, 15c or 15d are reacted with 9 where Y is to form 16a and 16b using the conditions described for the preparation of 10 where Y is -SO 2 R <2> . The compounds of formula I wherein D is can be prepared as described in scheme III by reaction of alkyne 17 in which W is Br or Cl, and k and m are defined herein earlier with the potassium salt of 1H-isoindole-1,3-(2H)-éion in N,N-dimethylformamide at room temperature to form the intermediate 18. Treatment of 13c with sodium hydride or sodium methoxide in N,N-dimethylformamide followed by reaction with 18 will give 19. Reaction of 19 with hydrazine or monomethylamine in refluxing ethanol gives the free amine 20 or the acid addition salt 21 as the hydrochloride , the hydrobromide, hydroiodity, phosphate, nitrate or sulfate. The sulfonyl chloride 9 where Y is -SO 2 R 2 is dissolved in ether and added to 20. After stirring for two to 16 hours the precipitate is collected, washed with water, ether, dried and crystallized to give 22 where Y is -SO 2 R <2> . Alternatively, 20 is dissolved in pyridine and a slight molar excess of 9 is added where Y is -SO 2 R <2> . The reaction mixture is stirred at or between room temperature and the reflux temperature of the solvent for eight to 16 hours. The pyridine is removed under reduced pressure and the residue is washed with water, dried and crystallized to form 22. Also, 2J will be. dissolved in dichloromethane containing an excess of triethylamine or N,N-diisopropylethylamine followed by 9 where Y is -SO 2 R <2> . The reaction mixture is stirred at or between room temperature and the reflux temperature of the solvent for two to 18 hours. The solvent is concentrated under reduced pressure, and the residue is washed with water, dried and crystallized to give 22 where Y is -SO 2 R 2 . In addition, 20 or 21 is traded with 9 where Y is to form 22 using the conditions for the preparation of 10 where Y is -SO2 R <2> . Furthermore, 20 or 21 is converted to 9 where Y is to form 22 using the conditions described for the preparation of l&wherein Y is -SO 2 R 2 . With reference to Scheme IV, the sulfonamide 23 is prepared according to Schemes I, II and III where Y is reacted with hydrogen sulphide to form the product 24. Reaction of 24 with α-bromoacetophenone 25 gives the thiazole 26. In addition, turnover of 23 where Y is mechiatrium azide in N,N-dimethylformamide at 120 to 130°C in the presence of ammonium chloride gives the tetrazole 27. As shown in Scheme V, 28 was prepared according to Schemes I, II and III by reacting with tris(formamido)methane and formamide at 160 to 165°C to form the pyrimidine 29. Furthermore, reaction of 28 with dimethylformamide dimethyl acetal will give the enamine 30. 30 is treated with hydrazine in refluxing ethanol to form the pyrazole 3_i or with formamidine to form 29. Substituting 31 with 9 gives 32. Cleavage of 29 with hydrazine or dimethylamine gives the amine 33. Reaction of 33 with 9 gives 34. As shown in Scheme VI, the benzenesulfonamide 35a, prepared according to Schemes I, II and III, wherein Y is reduced to the benzenesulfonamide 35 which is reacted with 2,5-dimethoxytetrahydrofuran in acetic acid to form the pyrrole compound 36. As shown in Scheme VII, 37a prepared according to Schemes I, II and III is reduced to 37 which is then reacted with triethyl orthoformate in the presence of sodium azide to form the tetrazole 38. Cleavage of 38 with hydrazine or methylamine gives the amine 39. Reaction of 39 with YCl where Y is as previously defined gives a compound of formula 40. This invention will be described in greater detail in connection with the following specific examples which are included for purposes of illustration. The reagents and intermediates used are either commercially available or can be synthesized by standard literature procedures by those skilled in the art of organic synthesis. Example 1 2- r4- r4-( 1H- imidazol- 1- phenoxyvlbutvn- 1H- isoindole- 1. 3( 2H)-dione To a solution of 4.0 g of sodium methoxide in 100 ml of dimethylformamide is added 10.0 g of 4-(1H-(imidazol-1-yl)phenol. After a few minutes, 18.2 g of 2-(4-bromobutyl) -1H-isoindole-1,3(2H)-dione, and the reaction mixture is stirred and heated on a steam bath for 16 hours. Addition to 2 L of cold water gives a precipitate which is collected, washed with 1 L of cold water and dried. Recrystallization from methylene chloride: hexane gives 14.7 of a solid melting at 105 to 107°C. Example 2 4-[ 4-( 1H-imidazole-1-yD-phenoxylbutanamine To a solution of 13.0 g of 2-[4-[4-1H-imidazol-1-yl)phenoxy]butyl]-1H-isoindole-1,3(2H)-dione (Example 1) in 250 ml refluxing ethanol is added to a 1.6 ml portion of anhydrous hydrazine. The mixture is stirred at reflux for 16 hours and taken to dryness in vacuo. The residue is mixed with 250 ml of ethanol and 25 ml of concentrated hydrochloric acid, and the mixture is stirred at reflux for two hours. The hot reaction mixture is filtered, and the precipitate is then washed with 100 ml of hot water. The combined filtrates are then taken to dryness in vacuo, leaving 8.4 g of the dihydrochloride salt of the title compound, m.p. 195-200°C. The title compound is obtained by dissolving the above dihydrochloride salt in H 2 0, treating with an excess of 10 N NaOH and extracting with dichloromethane. After drying and removal of the dichloromethane, the base is obtained as a low-melting solid. Example 3 4-(t-butvl)-N-r4-f4-(1H-imidazol-1-nphenoxy]butvl1benzenesulfonamide A solution of 3.0 g of 4-[4-(1 H-imidazol-1-yl)phenoxy]butanamine dihydrochloride (Example 2) is dissolved in 100 ml of H 2 O, and with stirring, 3.5 ml of 10 N NaOH is added, and 2.6 g of 4-(t-butyl)benzenesulfonyl chloride in 100 ml of diethyl ether are then added. The mixture is stirred at room temperature for four hours. The precipitate is collected, washed with 50 ml of water and 50 ml of diethyl ether, and air-dried. Recrystallization from 50% aqueous ethanol gives 2.6 g of the title compound, m.p. 138-140°C. Example 4 4-bromo-N-[4-[4-(1H-imidazol-1-yl)phenoxy1butyl]benzenesulfonamide When using the method in example 3 using 3.0 g of 4-bromobenzenesulfonyl chloride, 0.6 g of the desired product is obtained as a white solid, m.p. 134-136°C. Example 5 4- chloro- r4- f4-( 1 H- imidazole- 1 - vOphenoxybenzenesulfonamide The procedure in Example 3 is followed using 2.4 g of 4-chlorobenzenesulfonyl chloride. A yield of 1.6 g of the desired compound is obtained as a white solid, m.p. 122-123°C. Example 6 N-14-r4-(1H-imidazol-1-v1)phenoxybutylbutyl-2-naphthalenesulfonamide The method in example 3 is used using 2.6 g of 2-naphthalenesulfonyl chloride. A yield of 1.9 g of the title compound is obtained as a white solid, m.p. 157-158°C. Example 7 4- methyl- N-[ 4-[ 4-( 1 H- imidazole- 1- vDphenoxybutyl benzenesulfonamide By following the procedure in example 3 and using 2.2 g of 4-methylbenzenesulfonyl chloride, 0.8 g of the desired compound is obtained as a white solid, m.p. 96-98°C. Example 8 4- iodo- N-[ 4- f4-( 1 H- imidazole- 1- yDphenoxybenzenesulfonamide By applying the method in example 3 and using 3.0 g of 4-iodobenzenesulfonyl chloride, 3.2 g of the desired compound is obtained as a white solid, m.p. 150-152°C. Example 9 N-f4-f4-(1H-imidazol-1-yl)phenoxy]butylbenzenemethanesulfonamide By following the procedure in example 3 and using 2.1 g of benzenemethanesulfonyl chloride, 0.3 g of the desired compound is obtained as a white solid, m.p. 123-124°C. Example 10 N-f4-[4-(1H-imidazol-1-yl)phenoxy1butyl1-8-quinoline sulfonamide By applying the method in example 3 and using 2.4 g of 8-quinolinesulfonyl chloride, 1.8 g of the desired compound is obtained as a white solid, m.p. 131-3°C. Example 11 N-[ 4-[ 4- M H- imidazol- 1- yOphenoxy] butyl- 2- thiophenesulfonamide The title compound is prepared by the method in example 3 and using 2.0 g of 2-thiophenesulfonyl chloride; 1.9 of the desired compound is obtained as a solid, m.p. 121-122°C. Example 12 N-[ 4- r4-( 1 H- imidazol- 1- vl) phenoxv1butvn- 1, 2- dihydro- 1- metvl- 2- oxobenzfcd1indole- 6- sulfonamide 1,2-dihydro-1-methyl-2-oxobenz[cd]indole is dissolved in chlorosulfonic acid at room temperature. After 18 hours at room temperature, the solution is added to crushed ice during precipitation of the 6-sulfonyl chloride. This solid is collected, washed with water and dried in vacuo at room temperature. A dilute solution of 2.8 g of the above sulfonyl chloride in 200 ml of dichloromethane is added to a stirred mixture of 3.0 g of 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine dihydrochloride (Example 2) and 3.5 ml of 10 N NaOH. After six hours, the dichloromethane layer is separated, washed with water and dried over Na 2 SO 4 . Addition of an equal volume of hexane gives a yellow precipitate which is purified by recrystallization from ethanol; yield 0.8 g; m.p. 177-179°C. Example 13 2, 5- dichloro- N-[ 4-[ 4-( 1 H- imidazole- 1- vDphenoxylbutylbenzenesulfonamide The procedure in Example 3 is followed using 2.6 g of 2,5-dichlorobenzenesulfonyl chloride. The desired compound is obtained as a white solid, m.p. 144-146°C; yield 1.5 g. Example 14 4- trifluoromethyl- N-[ 4- r 4-( 1 H- imidazole- 1- phenoxyphenylbutylbenzenesulfonamide The title compound is prepared by the method in example 3 using 0.01 mol of 4-trifluoromethylbenzenesulfonyl chloride. The desired compound is obtained as a solid, m.p. 119-120°C; yield 1.0 g. Example 15 4-nitro-N-[4-[4-(1H-imidazol-1-vl)phenoxy1butyl]benzenesulfonamide The title compound is prepared by the method in example 3 using 2.4 g of 4-nitrobenzenesulfonyl chloride. The desired compound is obtained in 0.5 g yield as a solid, m.p. 156-157°C. Example 16 4- acetamido- N-[ 4-[ 4-( 1 H- imidazol- 1- yl) phenoxys1butyl] benzenesulfonamide The title product is prepared by the method in example 3 using 4-acetamidobenzenesulfonyl chloride. The desired product is obtained as a solid, m.p. 101-103°C; yield 1.9 g. Example 17 4-Methox- 4-[ 4-( 1H- imidazole- 1- phenoxybutylbenzenesulfonamide The title compound is prepared by the method in example 3 using 0.011 mol of 4-methoxybenzenesulfonyl chloride. The desired product is obtained as a solid, mp 106-107°C; yield 1.6 g. Example 18 N- r4-[ 4-( 1 H- imidazol- 1 - vOphenoxybutylbutyl- 1 - octanesulfonamide The procedure in Example 3 is followed using 2.3 g of octanesulfonyl chloride. The desired compound is obtained as a solid, mp 99-100°C; yield 2.0 g. Example 19 2, 4, 6-trimethyl-N-f4-f4-(1H-imidazole-1-yDphenoxybutylbenzenesulfonamide The title compound is prepared by the method in example 3 using 2.4 g of 2,4,6-trimethylbenzenesulfonyl chloride. The desired compound is collected as a solid, mp 130-131 °C; yield 0.8 g. _J <*> Example 20 N-[ 4-[ 4-( 1 H-imidazol- 1 -vl)phenoxy] butyl1- 2. 1 , 3-benzothiadiazole-4-sulphonamide The title compound is prepared by the method in Example 3 using 2.6 g of 2,1,3-benzothiadiazole-4-sulfonyl chloride. The desired compound is obtained as a solid, mp 112-114°C ; yield 0.8 g. Example 21 4-Cvano-N-[4-r4-(1H-imidazol-1-yl-)phenoxylbutylbenzenesulfonamide The title compound is prepared by the method in example 3 using 2.2 g of 4-cyanobenzenesulfonyl chloride The desired compound is obtained as a solid, mp 148-149°C; yield 2.0 g. Example 22; 4-butoxy-N-f4-f4-(1H-imidazol-1-vl)phenoxys1butvl]benzenesulfonamide Compound The solution is prepared by the method in example 3 using 2.8 g of 4-butoxybenzenesulfonyl chloride. The desired compound is collected as a solid, m.p. 103-105°C; yield 1.5 g. Example 23 N-f4-[4-(1H-imidazol-1-yl)phenoxy]butyl-1benzenesulfonamide The title compound is prepared by the method in example 3 using 1.4 ml of benzenesulfonyl chloride. The desired compound is collected as a solid, mp 110-111°C; yield 1.5 g. Example 24 N-f4-[4-(1H-imidazol-1-vl)phenoxy]butyl]-2.1,3-benzoxadiazole-4-sulfonamide The title compound is prepared by the method in example 3 by using 2.0 g of 2,1,3-benzoxadiazole-4-sulfonyl chloride. The desired compound is collected as a white solid, mp 125-126°C; yield 1.0 g. Example 25; 5-aminomethyl-N-f4-r4-(1H-imidazol-1-vl)phenoxys1butyl-2-thiophenesulfonamide A solution of 3.0 g of 5-benzoylaminomethyl-2-thiophenesulfonyl chloride in 100 ml of dichloromethane is added to a stirred mixture of 3.0 g of 4-[4-1H-imidazol-1-yl)phenoxy]butanamine dihydrochloride (Example 2) and 3.5 ml of 10 N NaOH in 100 ml of water. The mixture is stirred at room temperature for three hours, while a sticky precipitate forms. The precipitate is mixed with 100 ml of concentrated HCl and the mixture is stirred at reflux for 12 hours while dissolution takes place. The solution is taken to dryness in vacuo and the dihydrochloride salt of the title compound recrystallized from aqueous ethanol, mp 230-232°C (dec); yield 0.5 g. Example 26 2-r5-f4-(1H-imidazole-1-phenoxyphenylpentyl-1H-isoindole-1.3-(2H)-dione The title compound is essentially prepared by the method in example 1, in the 2-(5-bromopentyl)-1H-isoindole-1,3(2H)-dione replaces the 4-bromobutyl intermediate.Recrystallization of the collected solid from dichloromethane:hexane gives the desired product, mp 105-106°C Example 27 5-f4-(1H-imidazol-1-βDphenoxyphenylpentanamine 2-[5-[4-(1H-imidazol-1-yl)phenoxy]butyl]-1H-isoindole-1,3-(2H )-dione (Example 26) is cleaved with hydrazine in refluxing ethanol by the procedure of Example 2. The crude hydrochloride salt is dissolved in 20 parts of water, made basic with 10 N-NaOH, and the mixture is then extracted with 30 parts of dichloromethane. After drying with Na2SO4 the dichloromethane is removed in vacuo to give the desired compound as a clear oil, with the correct molecular weight as determined by mass spectrometry.Example 28 4-bromo-N-f5-[4-(1H-imidazole-1-vl)phenoxy 1pentyl]benzenesulfonamide 5-[4-(1H-imidazol-1-yl)phenoxy]pentanamine (Example 27) is converted to the title compound by the procedure of Example 4 to give the desired compound as a solid, m.p. 137-138°C. Example 29 N-[5-[4-(1H-imidazol-1-vPphenoxylpentylhexanesulfonamide) The desired product is obtained by using 5-[4-(1H-imidazol-1-yl)phenoxy]pentanamine (Example 27) and hexanesulfonyl chloride by the procedure of Example 3 which gives the title compound as a solid. - 1. 3(2H)-dione (E)-1,4-dichloro-2-butene and potassium phthalimide are added to dimethylformamide, and the mixture is stirred at room temperature for 18 hours. The reaction mixture is taken to dryness in vacuo. The residue is shaken with cold water, precipitating (E)-2-(4-chloro-2-buten-1-yl)-1H-isoindol-1,3(2H)-dione, which is purified by recrystallization from hf ixane; m.p. . 100-101 °C. A dilute solution of 16.0 g of 4-(1H-imidazol-1-yl)phenol in 250 ml of dimethylformamide is treated with 4.2 g of 60% NaH. To the suspension of the sodium salt is added 23.5 g of (E)-2-[4-chloro-2-buten-1-yl)-1H-isoindol-1,3(2H)-dione, and the reaction mixture o stirred and heated on a steam bath for 16 hours. The dimethylformamide is removed in vacuo, and the residue is stirred with 250 ml of water. The insoluble matter is collected, washed with water and dried. Recrystallization from ethanol gives the desired product as a solid, m.p. 170-171 °C. Example 31 (E)-4-f4-(1H-imidazol-1-vl)phenoxv1-2-buten-1-amine A solution of 26.2 g of (E)2-[4-[4-(1 H-imidazol-1-yl)phenoxy]-2-buten-1-yl]-1H-isoindol-1,3(2H)-dione (Example 30) in one liter of ethanol is treated with 5 ml of anhydrous hydrazine, and the mixture stirred at reflux for 18 hours. 25 ml of concentrated HCl are added to the reaction mixture and the mixture is cooled to room temperature. The precipitate is collected and washed with two portions of 300 ml of water. The filtrate and the aqueous washings are combined and evaporated to dryness in vacuo. The solid is treated with 25 ml of 10 N NaOH, the mixture saturated with solid K 2 CO 3 , and then extracted with 500 ml of dichloromethane. Removal of the dichloromethane in vacuo leaves a viscous oil which solidifies at room temperature. A portion is purified by recrystallization from hexane, and dried; m.p. 81-83°C; yield 0.5 g. Example 32 (E)-4-methyl-N-[4-[4-(1H-imidazol-1-yl)-phenoxy1-2-butene-1-ylbenzenesulfonamide A suspension of 3,4 g of (E)-4-[4-(1H-imidazol-1-yl)phenoxy]-2-buten-1-amine (Example 31) in 300 ml of diethyl ether and 5 ml of triethylamine is treated with a solution of 3 .0 g of 4-methyltoluenesulfonyl chloride in 100 ml of diethyl ether. The mixture is stirred at room temperature for 12 hours, heated under reflux for two hours and filtered hot. The precipitate is washed with 50 ml H20 and 100 ml ether and air dried. Recrystallization from ethanol gives the pure title compound, mp 140-142°C; yield 2.4 g7 Example 33 2- r4-(4-nitrophenoxv)butvn-1H-isoindol-1,3(2H)-dione A solution of 14.0 g of 4-nitrophenol in 250 ml of dimethylformamide is treated with 6 .0 g of sodium methoxide. After 15 minutes, 28.2 g of 2-(4-bromobutyl)-1H-isoindole-1,3(2H)-dione are added, and the mixture is then stirred at room temperature for 16 hours. The reaction mixture is diluted with 1500 ml of cold water, the precipitated solid is collected, washed with water and dried. Recrystallization from ethanol gives the desired compound, m.p. 112-114°C. Example 34 4-r4-nitrophenoxy1butanamine A suspension of 62.6 g of 2-[4-(4-nitrophenoxy)butyl]-1H-isoindole-1,3(2H)-dione (Example 33) in one liter of ethanol is treated with 6.5 ml of hydrazine, and the mixture then stirred at reflux for 18 hours. After cooling to room temperature, the precipitate is collected, washed with 250 ml of hot 2.5 N HCI, and 200 ml of hot H 2 0. The combined acid and water washings are evaporated to dryness to obtain the hydrochloride salt of the title compound. Mass spectrometry shows the presence of the title compound. The compound is used directly without further purification. Example 35 4-methyl-N-[4-(4-nitrophenoxy)butyl]benzenesulfonamide A solution of 8.8 g of 4-(4-nitrophenoxy)-butanamine hydrochloride (Example 34) in 200 ml of water is treated sequentially with 9 ml of 10 N NaOH, and a solution of 7.5 g of 4-methylbenzenesulfonyl chloride in 200 ml of diethyl ether. The reaction is stirred at room temperature for three hours, the precipitate is collected, washed with water and diethyl ether, and air-dried. Recrystallization from 50% aqueous ethanol gives the desired product as a solid, m.p. 87-88°C; yield 1.2 g. Example 36 4-methyl-N-f4-(4-aminophenoxy)butyl-benzenesulfonamide 5.0 g of 4-methyl-N-[4-(4-nitrophenoxy)-butyl]benzenesulfonamide (Example 35) is dissolved in 500 ml of ethanol, 1.5 ml of anhydrous hydrazine and 500 mg of 10% palladium on carbon are added, and the mixture then stirred under reflux for four hours. The reaction mixture is filtered hot. Cooling the filtrate to room temperature gives a precipitate, which is collected. The filtrate is reheated to boiling and used to re-extract the palladium carbon residue, and after filtration cooled to room temperature in which the precipitate was collected. The procedure is repeated until no further precipitate is formed on cooling to room temperature. After drying at 60°C in vacuum, the total precipitates weigh 3.3 g; m.p. 176-178°C. Example 37 2-f4-(4-aminophenoxy)butyl-1H-isoindole-1.3(2H)-dione A suspension of 6.8 g of 2-[4-(4-nitro-phenoxy)butyl]-1 H-isoindole-1,3(2H)-dione (Example 33) in 200 ml of ethanol is treated with 500 mg of 10% Pd on carbon, and reduced in a Parr hydrogenator. After filtration, concentration of the filtrate gives the desired product, m.p. 119-121°C; yield 4.3 g. Example 38 2- r4- f4-( 1H- tetrazole- 1- phenoxys1butyl- 1 H- isoindole- 1. 3( 2H)-dione To a solution of 17.7 g of 2-[4- (4-amino-phenoxy)butyl]-1H-isoindole-1,3(2H)-dione (Example 37) in a mixture of 250 ml of acetic acid and 80 ml of triethyl orthoformate is added 7.0 g of sodium azide, and the mixture is then stirred and heated on a steam bath for four hours. Concentration to dryness in vacuo leaves a residue which is triturated with 250 ml of water. The insoluble is collected, washed with water and dried. Recrystallization from ethanol gives the title compound, mp 143-145°C. Example 39 4- f4-(1H-tetrazol-1-vl)phenoxys1butanamine A suspension of 19.4 g of 2-[4-[4-(1H-tetrazol-1-yl)phenoxy]butyl]-1H-isoindol-1 ,3(2H)-dione (Example 38) in 400 mL of boiling ethanol is treated with 3 mL of anhydrous hydrazine, and the mixture is stirred at reflux for 16 h. The precipitate is collected, washed with 200 mL of hot 1.5 N HCl, and 50 ml H2 0. The combined ethanol, hydrochloric acid and water filtrates are heated to dryness in vacuo to form the hydrochloride salt of the title compound. A portion of the salt was recrystallized from hot ethanol, m.p. 197-198°C (dec.). Example 40 4-bromo-N-[4-f4-(1H-tetrazol-1-vol-phenoxy-v-butyl-benzenesulfonamide) A solution of 2.7 g of 4-[4-(1H-tetrazol-1-yl)phenoxy]butanamine hydrochloride (Example 39 ) in 100 ml of water is treated sequentially with 3.5 ml of 10 N NaOH and a solution of 2.7 g of 4-bromobenzenesulfonyl chloride in 100 ml of diethyl ether. The mixture is stirred at room temperature for 1.5 hours, the precipitate is collected, washed with diethyl ether and water, and air-dried. Recrystallization from ethanol gives the pure compound, mp 109-110°C; yield 1.6 g. Example 41 4-methyl-N-r4-f4-(1H-tetrazol-1-yl) phenoxybutyl-1benzenesulfonamide The compound in question is essentially prepared by the method in Example 40, in which 4-methylbenzenesulfonyl chloride replaces the 4-bromobenzenesulfonyl chloride. The desired compound is collected as a solid, m.p. 127-128°C. Example 42 2- f4-( 4- acetvlphenoxv) butvll- 1 H- isoindole- 1. 3( 2H)-dione The compound in question is produced essentially by the method in ex Example 33, in which 1-(4-hydroxyphenyl)-ethanone replaces the 4-nitrophenol. Recrystallization of the collected solid from ethanol gives the desired product, m.p. 112-114°C. Example 43 1-f4-(4-aminobutoxy)phenylethanone A suspension of 13.5 g of 2-[4-(4-acetyl-phenoxy)butyl]-1H-isoindole-1,3(2H)-dione in 500 ml of ethanol is treated with 1.4 ml of anhydrous hydrazine, and the mixture stirred at reflux for nine hours. After cooling to room temperature, the precipitate is collected. Concentration of the filtrate gives the crude title compound which is used directly for further synthesis. Example 44 1-f4-f4-(4-bromobenzene-sulfonamido)butoxx1phenyl]ethanone The desired product is prepared using the conditions of Example 40, using 1-[4-(4-aminobutoxy)phenylethanone instead of 4-[4- (1H-tetrazol-1-yl)-phenoxy]butanamine; m.p. 129-130°C. Example 45 2-r4-r4-(pvhmidin-4-vl)phenoxvlbutvH-1H-isoindole-1.3(2H)-dione A mixture of 10.0 g of 2-[4-(4-acetylphenoxy]-butyl ]-1H-isoindole-1,3(2H)-dione (Example 42) 10.0 g of tris(formamido)methane, and 20 ml of formamide are combined, and the mixture stirred and heated at 160-165°C in eight hours. After dilution with 100 ml water, the mixture is made basic with 10 N NaOH, the precipitate collected, washed with water and air dried. Recrystallization from ethanol gives the pure compound, mp 100-102°C; yield 5.0 g. Example 46 4-f4-(pyrimidin-4-vl)phenoxy1butanamine A suspension of 4.6 g of 2-[4-[4-(pyrimidin-4-yl)phenoxy]butyl]-1H-isoindole-1,3( 2H)-dione (Example 45) in 200 mL of boiling ethanol is treated with 0.8 mL of anhydrous hydrazine, and the mixture then heated at reflux for nine hours. The hot suspension is filtered. The precipitate is washed with 125 mL of 1.5 N HCl. The combined HCI and ethanol filtrates are heated to dryness in a vacuum with formation of hydrochloride salt tet of the title connection. Mass spectrometry shows that the residue must be the title compound, and the salt is used for synthesis without further purification, m.p. 208-210°C (dec.). Example 47 4-bromo-N-r4-r4-(pyrimidin-4-vl)phenoxybutylbutylbenzenesulfonamide The compound in question is essentially prepared by the method in example 4, in which 4-[4-(pyrimidin-4-yl)phenoxy]butanamine hydrochloride (Example 46) replaces the 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine hydrochloride. The desired compound is obtained as a solid after recrystallization from 50% aqueous ethanol, m.p. 131-133°C. Example 48 (E)-2-f4-f4-f3-(dimethylamino)-1-oxo-2-propenvnphenoxyvlbutvn-1H-isoindole-1.3(2H)-dione A solution of 25 g of 2-[4-( 4-acetylphenoxy)butyl]-1H-isoindole-1,3(2H)-dione (Example 42) and 25 ml of dimethylformamide dimethyl acetal in 50 ml of dioxane are heated on a steam bath for 16 hours. The volatile components are removed in vacuo, forming a sticky reddish-brown solid. A portion is crystallized from dichloromethane:hexane; m.p. 109-111°C. Example 49 4- r4-(1H-pyrazol-3-vl)phenoxs1butanamine A suspension of 21.2 g of (E)-2-[4-[4-[3-(dimethylamino)-1-oxo-2-propenyl ]phenoxy]butyl]-1H-isoindole-1,3(2H)-dione (Example 48) in 300 ml of boiling ethanol is treated with 6 ml of anhydrous hydrazine. A suspension develops rapidly, necessitating the addition of 200 ml of additional ethanol to allow stirring. With stirring, 35 ml of concentrated HCI are then added, the mixture is heated at reflux for a further hour, and filtered hot. The insoluble matter is washed with 200 ml of boiling water. The combined filtrates are heated to dryness in vacuo to form the hydrochloride salt of the title compound as shown by mass spectrometry. The product is used for synthesis without further purification. Example 50 4-bromo-N-f4-r4-(1H-pyrazol-3-vl)phenoxv1butyl1benzenesulfonamide The title compound is essentially prepared by the method in example 40, in which 4-[4-(1H-pyrazol-3-yl)phenoxy ]butanamine hydrochloride (Example 49) replaces the 4-[4-(1H-tetrazol-1-yl)phenoxy]butanamine hydrochloride. The resulting compound is recrystallized from 50% aqueous ethanol, m.p. 157-158°C. Example 51 2-[ 4-(4-Cvanophenoxy)butyl]-1H-isoindole-1.3(2H)-dione The title compound is essentially prepared by the method in Example 33, in which 4-hydroxybenzonitrile replaces the 4-nitrophenol. The resulting solid is collected, m.p. 129-130°C. Example 52 4-(4-aminobutoxy)benzonitrile A suspension of 48.0 g of 2-[4-(4-cyano-phenoxy)butyl]-1H-isoindole-1,3(2H)-dione (Example 51) in a liter of refluxing ethanol is heated with 10 ml of anhydrous hydrazine. The mixture is stirred at reflux for 14 hours. After cooling to room temperature, the precipitate is filtered off and washed with 100 ml of ethanol. The ethanol filtrates are combined and heated to dryness in vacuo. The oil is dissolved in 100 ml of ethanol containing 15 ml of concentrated hydrochloric acid. Concentration of the solution in vacuo gives the crude hydrochloride salt of the title compound, purified by recrystallization from ethanol; m.p. 144-145°C; yield 7.2 g. Example 53 4-methyl-N-[4-(4-cyanophenyloxy)butenebenzenesulfonamide A solution of 3.4 g of 4-(4-aminobutoxy)benzonitrile hydrochloride (Example 52) in 100 ml of water is treated in sequence with 3.5 ml of 10 N NaOH and 3.5 g of 4-methylphenylsulfonyl chloride in 100 ml of diethyl ether. The mixture is stirred at room temperature for two hours during the formation of a precipitate. The solid is collected, washed with water and diethyl ether, dried, and recrystallized from 50% aqueous ethanol; m.p. 107-108°C; yield 3.5 g. Example 54 4-methyl-N-[ 4-[ 4-( 1H- tetrazole-5- vl) phenoxy-1-butylbenzenesulfonamide A mixture of 3.4 g of 4-methyl-N-[4-(4- cyanophenoxy)butyl]benzenesulfonamide (Example 53), 1.3 g of sodium azide, 1.5 g of ammonium chloride, and 25 ml of dimethylformamide are stirred at 120-130°C (in an oil bath) for 16 hours. The reaction mixture is added to 200 ml of water, and the resulting solution is then acidified to pH 4-5 with acetic acid. The precipitate that forms is collected, washed with water, dried and recrystallized from boiling ethanol. Dilution gives the pure compound, m.p. 180-182°C; yield 2.4 g. Example 55 " 4-methyl-N-f4-(4-thiocarbamylphenoxy)butylbenzenesulfonamide A solution of 3.5 g of 4-methyl-N-[4-(4-cyanophenoxy)butyl]benzenesulfonamide (Example 53) in a mixture of 30 ml of pyridine and 5 ml of triethylamine is gassed with a slow stream of hydrogen sulfide for 30 minutes, and placed in a stoppered flask. After seven days the volatile components are removed in vacuo. The oily residue is recrystallized from 50 % aqueous ethanol, forming the pure compound as yellow crystals, mp 140-141 °C; yield 3.0 g. Example 56 N-Dimethylaminomethylidene-4-r(4-methylphenyl- sulfonamido)butyloxy1thiobenzamide 3.6 g of 4-Methyl-N-[4-(4-thiocarbamyl-phenoxy)butyl]benzenesulfonamide is added to 30 ml of dimethylformamide dimethyl acetal, and the mixture is stirred at room temperature for one hour.The precipitate is collected, washed with diethyl ether and dried in vacuo at 40°C. Yield of the title compound is 3.9 g, mp 115-117° C. Example 57; 4-metvl-N-r4-f4-f( 4-chlorophen vl) thiazole-2-n-phenoxy-n-butyl-benzenesulfonamide A solution of 1.5 g of 2-bromo-1-(4-chlorophenyl)ethanone and 2.5 g of 4-methyl-N-[4-[4-(thiocarbamylphenoxy]butyl] benzenesulfonamide (Example 55) in 100 ml of ethanol is stirred at reflux for 17 hours. Cooling the solution gives a precipitate which is collected, washed with ethanol and dried. The precipitate is stirred in 200 ml saturated NaHCO 3 solution for 30 minutes. The insoluble matter is collected, washed with water and dried. Recrystallization from ethanol gives the pure compound, m.p. 158-159°C; yield 2.2 g. Example 58 2-r4-(4-phenylphenoxy)butyl-1H-isoindole-1.3(2H)-dione The compound in question is prepared by the method in example 33 in which 4-phenylphenbl replaces the 4-nitrophenol . The resulting solid is collected, m.p. 110-111°C. Example 59 4-(4-phenylphenoxy)butanamine The title compound is essentially prepared by the method in example 34 in the 2-[4-(4-phenylphenoxy)-butyl]-1H-isoindole-1,3(2H)-dione ( example 58) replaces 2-[4-(4-nitrophenoxy)butyl]-1H-isoindole-1,3(2H)-dione. The crude isolated hydrochloride salt has the expected molecular weight as shown by mass spectrometry, and is used directly in further synthesis. Example 60 4-methyl-N-[4-(4-phenylphenoxy)butyl-1benzenesulfonamide The compound in question is essentially prepared by the method in example 35 in which 4-(4-phenylphenoxy)butanamine hydrochloride replaces the 4-[4-nitrophenoxy)butanamine hydrochloride. After recrystallization from 50% aqueous ethanol, the pure compound is obtained as a solid, m.p. 119-120°C. Example 61 2-[ 4-( 4-Phenvlcarbonylphenoxyvofutvn- 1H- isoindole- 1, 3( 2HVdione) The compound in question is essentially prepared by the method in example 33 in which (4-hydroxyphenyl)phenylmethanone replaces the 4-nitrophenol. Recrystallization of the the crude product from methanol gives white crystals, m.p. at 53-55°G* Example 62 4-f( 4-phenylcarbonylphenoxy] butanamine The hydrochloride salt of the title compound is essentially prepared by the method of Example 34 in the 2-[4-(4-phenylcarbonyl -phenoxy)butyl]-1H-isoindole-1,3(2H)-dione (Example 61) replaces 2-[4-(4-nitrophenoxy)butyl]1H-isoindole-1,3(2H)-dione. the solid is collected, mp 188-190° C. Example 63 4-bromo-N-[ 4-(4-phenylcarbonylphenoxy)butyl-benzenesulfonamide To a solution of 2.0 g of 4-[(4-phenylcarbonylphenoxy)butanamine hydrochloride (Example 62) in a mixture of 40 ml of pyridine and 3 ml of triethylamine, 2.0 g of 4-bromobenzenesulfonyl chloride is added. The reaction mixture is stirred at room temperature for 18 hours, o PP is heated on a steam bath for one hour, and then added to 250 ml of water. Cooling at 0°C gives an oil which is dissolved in 100 ml of dichloromethane. Addition of 150 ml of hexane is followed by concentration to boiling (steam bath), and the mixture is cooled at -10°C. An oily solid is precipitated, and fine white crystals are produced in the supernatant solvent. These are carefully separated and dried; m.p. 71-73°C; recovery 0.2 g. Example 64 3-chloro-N-[4-(4-phenylcarbonylphenoxy)butyl-1benzenesulfonamide The title compound is essentially prepared by the method in example 53, in which 3-chlorophenylsulfonyl chloride replaces 4-methylphenylsulfonyl chloride to form the desired product. Example 65 2- n0-( 4-( 1 H- imidazol- 1 - vl) phenoxv1decvll- 1 H- isoindole- 1. 3( 2H)-dione The title compound is essentially prepared by the method in example 1 in which 2-(10-bromodecyl)-1H-isoindole-1,3(2H)-dione replaces the 4-bromobutyl intermediate. After recrystallization from dichloromethane:hexane, the desired compound is collected, m.p. 90-91 °C. Example 66 ( example 65) is converted to the free amino derivative by treatment with hydrazine in refluxing ethanol solution. A portion is converted to the hydrochloride salt by treatment with concentrated hydrochloric acid in ethanol to form the desired compound, mp 190-192°C. The free base is obtained at treatment with an excess of 10 N NaOH. Example 67 N- f 10-[ 4-( 1 H- imidazol- 1 - vhphenoxvldecvll- 2- naphthalenesulfonamide A suspension of 2.5 g of 10-[4-(1H-imidazol-1-yl)phenoxy]decanamine (Example 66) in 250 ml of diethyl ether containing 3 ml of triethylamine is stirred while adding 2.0 g of 2-naphthalenesulfonyl chloride . The reaction mixture is stirred at room temperature for 72 hours, and 50 ml of H 2 O is added. The solvents are decanted off leaving a viscous solid. The solid is dissolved in 100 ml of 50% aqueous ethanol. Careful concentration under a gentle stream of air gives a crystalline solid. The solid is collected, washed with water and dried in vacuo at room temperature; m.p. 112-115°C; yield 0.2 g. Example 68 4- methyl- N-[ 4-( 4- methanesulfonamido) phenoxy) butenebenzenesulfonamide A solution of 3.2 g of 4-methyl-N-[4-(4-aminophenyloxy)butyl]benzenesulfonamide (Example 36) in 50 ml of pyridine is stirred and treated with 1.5 g of methanesulfonyl chloride. The reaction mixture is stirred and heated on a steam bath for four hours, then heated to dryness in vacuo. The residue is stirred with 50 ml of water, and acidified to pH < 2 with concentrated hydrochloric acid. The precipitate is collected, washed with water and air-dried. Recrystallization from 50% aqueous ethanol followed by cooling at -10°C gives 2.0 g of the desired compound, m.p. 121-122°C. Concentration of the mother liquor gives a further 0.4 g of product. Example 69 2- f4-(4-acetamido)phenylthiolbutyl-1H-isoindole-1.3-(2H)-dione To a solution of 5.6 g of 95% sodium methoxide in 400 ml of ethanol is added 16.7 g of 4-acetamido-benzenethiol, and the mixture is stirred at room temperature for 15 minutes, while 28.2 g of 2-(4-bromobutyl )-1H-isoindole-1,3(2H)-dione is added. The reaction mixture is stirred and heated under reflux for six hours, and 100 ml of water is added. The solution is concentrated to approximately a 250 ml volume, and stirred at room temperature overnight. The precipitate present is collected, washed with water and air dried. Recrystallization from 50% aqueous ethanol gives the desired product, m.p. 113-114°C; yield 33.0 g. Example 70 4-[4-(acetamido)phenylthio1butanamine To a solution of 26.0 g of 2-[4-(4-acetamidophenylthio)butyl]-1H-isoindole-1,3(2H)-dione (Example 69) in 500 ml of boiling ethanol is added 4 ml of anhydrous hydrazine and reflux is continued for 20 hours. After cooling to room temperature, the precipitate present is collected and washed with 100 ml of ethanol. The ethanolic filtrate is heated to dryness in vacuo. The viscous oil residue is shaken with 200 ml of 1 N hydrochloric acid, and the insoluble matter is filtered off. The filtrate is made alkaline with 10 N sodium hydroxide to form an oil which crystallizes when the mixture is cooled to 0°C. The crystals are collected, washed with cold water and air dried; yield 13.3 g. Mass spectroscopy of the product gives a molecular weight of 238, in agreement with that expected for 4-[4-(acetamidophenylthio]butanamine. Treatment with concentrated hydrochloric acid in ethanol solution gives the hydrochloride salt, m.p. 167-169°C. Example 71 4-methyl-N-[ 4-[ 4-(acetamido)phenylthio1butyl]benzenesulfonamide To a solution of 7.2 g of 4-[4-(acetamido)phenylthio]butanamine (Example 70) in 100 ml of dichloromethane containing 8 ml of triethylamine is added 6.2 g of 4-methylbenzenesulfonyl chloride. The mixture is then stirred under reflux for six hours. The solvents are removed in vacuo. The residue is rubbed out with two portions of 100 ml of water. The insoluble portion is recrystallized from aqueous ethanol. At first the product precipitates as an oil, but after standing, crystals are obtained, m.p. 104-105°C; yield 6.6 g. Example 72 4-methyl-N-[4-(4-aminophenylthio)butyl]benzenesulfonamide A mixture of 5.3 g of 4-methyl-N-[4-(4-acetamidophenylthio)butyl]benzenesulfonamide (Example 71), 25 ml of concentrated hydrochloric acid, and 100 ml of ethanol is combined and stirred under reflux for 20 hours. The reaction mixture is heated to dryness in vacuo. The residue is shaken with 200 ml of water and made alkaline to pH > 14 with 10 N sodium hydroxide. The resulting precipitate is collected, washed with water, and dried, 140-142°C; yield 2.8 g. Example 73 4- methvl- N- f4-( 4- methanesulfonamidophenylthio) butyl1benzenesulfonamide A solution of 2.4 g of 4-methyl-N-[4-(4-aminophenylthio)butyl]benzenesulfonamide (Example 72) in 50 ml of pyridine is treated with 1.05 g of methanesulfonyl chloride, and the solution is stirred and heated at steam bath for six hours. The pyridine is then removed in vacuo. The residue is shaken with 100 ml of water, and the mixture acidified to below pH=2 with concentrated hydrochloric acid. The precipitate is collected, washed with water and dried. "Recrystallization from 50% aqueous ethanol gives shiny white crystals after drying, mp 95-96°C; yield 1.2 g. Example 74 4-methyl-N-r4-(4-acetamidophenylsulfonyl)butyl-1benzenesulfonamide A solution of 2.0 g of 4-methyl-N-[4-(4-acetamidophenylthio)butyl]benzenesulfonamide (Example 71) in 100 ml of acetic acid is heated at 90-95°C. After adding 10 ml of 30% hydrogen peroxide, the mixture is stirred at steam bath temperature for 16 hours. Dilution with 300 ml of cold water gives an oily precipitate which is collected on a diatomaceous earth filter mat. Extraction of the filter mat with 250 ml of boiling acetone, followed by concentration to dryness in vacuo gives an oily residue. Recrystallization from 50% aqueous ethanol gives the desired compound, m.p. 93-95°C; yield 0.3 g. Example 75 4- methyl- N-[ 4-( 4- pyrrole- 1- phenylcyclohexylbutylbenzenesulfonamide A mixture of 3.2 g of 4-methyl-N-[4-(4-aminophenyloxy)butyl]benzenesulfonamide (Example 36), 1.5 g of 2,5-dimethoxytetrahydrofuran, and 50 ml of acetic acid is stirred and heated at the steam bath for 16 hours. The reaction mixture is heated to dryness in vacuo. The residue is shaken with 150 ml of dichloromethane and 150 ml of saturated sodium bicarbonate solution. The dichloromethane layer is separated, dried over Na 2 SO 4 and diluted with 100 ml of hexane. The solution is concentrated until clouding, and then cooled at -10°C. The precipitate that forms is collected, washed with hexane, and air dried; m.p. 124-126°C; yield 0.2 g. Example 76 4- chloro- N- f4- f4-( 1 H- imidazole- 1 - vDiphenoxyvolbutenebenzamide A solution of 2.8 g of 4-[4-(1H-imidazol-1-yl)phenoxy]butylamine hydrochloride (Example 2) in 50 ml of water is treated sequentially with 4 ml of 10 N NaOH and 2.0 g of 4-chlorobenzoyl chloride in 100 ml of diethyl ether. Stirring at room temperature for three hours gives a precipitate which is collected, washed with diethyl ether and water, and air-dried. Recrystallization from 33% aqueous ethanol gives the desired product, m.p. 138-139°C; yield 1.3 g. Example 77 4- bromo- N-[ 4- f4-( 1 H- imidazole- 1- vylphenoxybutylbenzamide The title compound is essentially prepared by the method in Example 76, in which 4-bromobenzoyl chloride replaces 4-chlorobenzoyl chloride; m.p. 140-141°C. Example 78 2- bromo- N- f4-[ 4-( 1 H- imidazol- 1 - vDphenoxysulfylbutylbenzamide The title compound is prepared by the method in example 76 in which 2-bromobenzoyl chloride replaces the 4-chlorobenzoyl chloride. Recrystallization from 50% aqueous methanol gives the desired product, m.p. 138-139°C. Example 79 N-[ 4-[ 4-( 1 H- imidazol- 1- vDphenoxybutylbutylbenzamide The title compound is prepared by the method in example 76 in which benzoyl chloride replaces the 4-chlorobenzoyl chloride. After recrystallization from 33% aqueous ethanol, the compound has a m.p. at 117-118°C. Example 80 4- methyl- N-[ 4-[ 4-( 1 H- imidazol- 1 - phenoxyphenylbutulfonezamide 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine dihydrochloride (Example 2) is treated with 10 N NaOH (mixture pH > 12). The oil present is extracted with dichloromethane. Removal of the dichloromethane in vacuo gives 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine as a viscous oil which is used directly for further synthesis. A solution of 2.3 g of 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine in 25 ml of pyridine is treated with 1.8 g of 4-methylbenzoyl chloride. After heating at steam bath temperature for one hour, the reaction mixture is added to 400 ml of water with precipitation of a viscous oil. The aqueous phase is decanted off. A solution of the oil in 200 ml of hot 50% aqueous methanol, followed by cooling at -10°C gives a sticky precipitate, but a white crystalline precipitate develops in the supernatant solvent. The crystals are carefully collected, washed with cold H 2 0 and dried in vacuo at room temperature, m.p. 128-130°C; yield 0.7 g. Example 81 4-methoxy-N-f4-f4-(1H-imidazol-1-yOphenoxylbutylbenzamide) A solution of 2.3 g of 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine (Example 2) in 50 ml of dichloromethane containing 2 ml of pyridine is treated with 2.0 g of 4-methoxybenzoyl chloride. The reaction mixture is allowed to stand at room temperature for 18 hours and is then heated at reflux for one hour. The volatiles are removed in vacuo. The residue is partitioned between 100 ml dichloromethane and 100 ml water. The dichloromethane layer is dried over Na 2 SO 4 and then heated to gentle boiling. Hexane is then added to flash and the mixture cooled at -10° C. A sticky precipitate results and crystals develop in the supernatant solvent These are collected, washed with hexane, and dried in vacuo at room temperature, mp 125-126°C, yield 0.4 g. --t Example 82 N-[ 4-[ 4-( 1 H- imidazol- 1- vl) phenoxy 1-butyl 1- 1- naphthalenecarboxamide The preparation of the title compound is essentially carried out according to the procedure in Example 81 in which 1-naphthoyl chloride replaces the 4-methoxybenzoyl chloride. After removal of the volatiles, the residue is treated with 100 ml of 1 N NaOH and 100 ml of diethyl ether, and the mixture then cooled at 0°C overnight. The precipitate is collected and recrystallized from 50% aqueous ethanol and dried; m.p. 157-159°C. Example 83 4-fluoro-N-r4-r4-(1H-imidazole-1-yDphenoxylbutvUbenzamide) The title compound is prepared essentially according to the procedure in example 81 in which 4-fluorobenzoyl chloride replaces the 4-methoxybenzoyl chloride. The crude product is recrystallized from diethyl ether and dried, m.p. 122-123°C. Example 84 4-iodo-N-[4-f4-(1H-imidazol-1-vDphenoxybutylbenzamide) The title compound is prepared essentially according to the procedure in example 76 in which 4-iodobenzoyl chloride replaces the 4-chlorobenzoyl chloride. The pure compound is obtained after recrystallization from 50% aqueous ethanol, mp 143-145°C. Example 85 N-(4-bromophenyl)-N'-f4-[4-(1H-imidazol-1-yl)phenoxy]butylurea Solutions of 4-[(4-imidazol-1-yl)phenoxy]butanamine (Example 2) in diethyl ether (1.6 g in 400 ml) and 4-bromophenyl isocyanate in diethyl ether (1.4 g in 100 ml) are mixed together. A white precipitate forms immediately. After 30 minutes the title compound is collected, washed with diethyl ether and dried, m.p. 157-159°C; yield 1.7 g. Example 86 4-bromo-N-r5-f4-(1H-imidazol-1-vDphenoxylpentylbenzamide) A solution of 2.9 g of 5-[4-(1H-imidazol-1-yl)phenoxy]pentanamine (Example 27) in 150 ml of dichloromethane and 100 ml of 1 N NaOH, are combined and stirred vigorously while adding 2.8 g of 4-bromobenzoyl chloride. The reaction mixture is stirred at room temperature for 20 hours, the dichloromethane layer is separated and dried over Na 2 SO 4 . The dichloromethane solution is diluted with 200 ml of hexane and the solution concentrated to clar.Cooling the mixture to room temperature gives the desired product as white crystals, mp 150-151 °C, yield 1.4 g. Example 87 O. Q'- diphenyl- N-[ 4-[ 4-( 1 H- imidazole- 1- phenylcycloxylbutylphosphoramide A solution of 3.0 g of 4-[4-(1H-imidazol-1-yl)phenoxy]butanamine hydrochloride (Example 2) in 100 ml of water is stirred and treated with 3.3 ml of 10 N sodium hydroxide. A solution of 2.9 g of 0.0', diphenylphosphoryl chloride in 100 ml of diethyl ether is added and the mixture stirred at room temperature for six hours. The diethyl ether is removed in a stream of air, leaving a viscous solid in the aqueous phase. The mixture is cooled to 0°C and the water is decanted off. The solid is dissolved in 100 ml of ethyl acetate and the solution is then dried over Na 2 SO 4 . The ethyl acetate solution is cooled to 0°C and diluted with 300 ml of hexane. Cooling at -10°C leads to the formation of a precipitate which is collected, washed with hexane, and dried in vacuo at 40°C to give 1.5 g of the title compound, m.p. 110-112°C. Example 88 P. P-diphenyl-N-[4-f4-(1H-imidazol-1-yl)phenoxys1butyl1phosphinamide A mixture consisting of 3.0 g of 4-[4-(1H-imidazole-1- yl)phenoxy]butanamine dihydrochloride (Example 2) is triturated with 3.5 ml of 10 N sodium hydroxide. 150 ml of methylene chloride is added to the mixture followed by 20 g of sodium sulphate. After stirring for 25 minutes, the solids are removed by filtration. 3 ml of triethylamine and then 2 ml of diphenylphosphine chloride are added to the filtrate with stirring. The reaction mixture is stirred at room temperature for two hours, washed with 100 ml of water and dried over sodium sulfate. Removal of the methylene chloride in vacuo leaves a viscous oil which crystallizes on stirring with 25 ml of diethyl ether. The precipitate is collected, washed with 75 ml of diethyl ether, and dried in vacuum at room temperature. The melting point is 106-107°C. Example 89 N-[ 4-[ 4-( 1H- tetrazole- 1- vl) phenoxy1butvn- 2, 1, 3- benzothiadiazole- 4- sulfonamide A mixture consisting of 0.9 g of 4-[4-(1H-tetrazol-1- yl)phenoxy]butanamine hydrochloride (Example 39) and 1 ml of 10 N sodium hydroxide are stirred until all the solid has disappeared. The suspension is stirred with 150 ml of dichloromethane and 7 g of anhydrous sodium sulfate for 30 minutes. The insoluble material is removed by filtration. The filtrate is then triturated with 1.5 ml of triethylamine followed by a solution of 0.93 g of 2,1,3-benzothiadiazole-4-sulfonyl chloride in 25 ml of dichloromethane. The reaction mixture is stirred at room temperature for 16 hours. It is then washed with an equal volume of water. After drying with anhydrous Na 2 SO 4 , the dichloromethane is removed in vacuo, leaving a yellow solid. Recrystallization from a mixture of dichloromethane:diethyl ether gives 0.7 g of the pure product, m.p. 142-143°C. Example 90 3- bromo- N-[ 4-[ 4-( 1H- imidazole- 1- n-phenoxybutyl-1-benzamide The title compound is prepared by the method according to example 76 in which 3-bromobenzoyl chloride replaces the 4-chlorobenzoyl chloride. Recrystallization from ethanol gives the desired product, m.p. 89-91 °C. Example 91 2- r3- f4-( 1 H- imidazol- 1 - vhphenoxvlpropvH- l H- isoindole- 1. 3( 2HVdione To 100 ml of absolute ethyl alcohol is added 1.01 g of sodium followed by stirring for 30 minutes, and the addition of 10.7 g of N-(3-bromopropyl)phthalimide. After refluxing for four hours, the mixture is cooled to room temperature, methylene chloride is added and filtered to remove insolubles. The filtrate is dried (MgSO 4 ) and evaporated in vacuo to give 13.5 g of residue. A sample is crystallized from ethyl alcohol to form a golden brown solid, mp 113-117°C. Example 92 3-[ 4-( 1H-imidazole-1- vDphenoxyvlpropanamine A mixture of 17.0 g of 2-[3-[4-(1H-imidazol-1-yl)phenoxy]propyl]-1H-isoindole-1,3(2H)-dione (Example 91) and 2, 8 ml of hydrazine hydrate in 150 ml of ethyl alcohol is heated under reflux for three hours. The reaction mixture is cooled and 225 mL of 3N HCl is added, followed by heating at reflux for two hours and standing at room temperature for 18 hours. The reaction mixture is filtered, and the filtrate is evaporated in vacuo to a residue which is washed with ethyl alcohol and ether, dried in a vacuum oven to give 12.0 g of the dihydrochloride salt of the title compound as a golden brown solid, m.p. 208-220°C. Example. 93 4- bromo- N- f3-[ 4-( 1H- imidazol- 1- vDphenoxylpropyllbenzamide A mixture of 2.04 g of 3-[4-(1H-imidazol-1-yl)phenoxy]propanamine dihydrochloride (Example 92) in 70 ml of methylene chloride is treated with 21 ml of 1 N NaOH followed by 1.54 g of 4-bromobenzoyl chloride with stirring at room temperature for 18 hours. Additional methylene chloride and 5 ml of 1 N NaOH are added and the organic layer separated, washed with water and filtered. The organic layer is evaporated in vacuo to a residue which is washed with ether and dried to give 1.3 g of an off-white solid, m.p. 183-185°C. Example 94 N- r4- f3-( 1. 3- dihydro- 1. 3- dioxo- 2H- isoindole- 2- vhpropoxv1phenvnacetamide To a solution of 15.1 g of 4-acetamidophenol in 150 ml of N,N-dimethylformamide, 4.0 g of 60% sodium hydride in mineral oil is added followed by stirring until gas evolution stops. A 26.8 g portion of N-(3-bromopropyl)phthalimide is added and the reaction mixture heated on a steam bath for 16 hours. The reaction mixture is poured into one liter of cold water, the resulting solid is collected and washed with one liter of cold water, and the solid is vacuum dried. A 5 g sample is crystallized from 25 ml of ethanol to form 1.5 g of solid, m.p. 155-157°C. The remaining sample is crystallized from ethanol to give 23.4 g of solid, m.p. 154-156°C. Example 95 2- r3-(4-aminophenoxy)propyl1-1H-isoindole-1.3(2H)-dione A solution of 10.0 g of N-[4-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propoxy]phenyl]acetamide (Example 94) in 500 ml of ethanol is treated with 100 ml HCI, and heated at reflux for eight hours, and allowed to stand at room temperature for 18 hours. The precipitate is collected, washed with 50 ml of ethanol and air-dried to give 8.6 g of solid as the hydrochloride salt. A 1.5 g sample is crystallized from ethanol water to give 1.2 g of the HCl salt of the title compound, m.p. 250-260°€. Example 96 N-f4-f3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propoxy1phenylmethanesulfonamide A 7.0 g sample of 2-[3-(4-aminophenoxy)propyl]-1H-isoindole-1,3(2H)-dione monohydrochloride (Example 95) is added to 100 ml of pyridine, 2.2 ml of 10 N NaOH and 2.5 methanesulfonyl chloride. The mixture is stirred at room temperature for six hours and one hour on a steam bath. The reaction mixture is poured into 900 ml of cold water and stored at 0°C for 18 hours. The precipitate is collected, washed with 200 ml of water and dried to form 6.5 g of solid. A 1.0 g sample is crystallized from 100 ml of boiling ethanol after treatment with activated carbon to form 0.6 g of solid, m.p. 176-178°C. Example 97 3-[4-(methanesulfonylamino)phenox]propanamine A suspension of 5.5 g of N-[4-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propoxy]phenyl]methanesulfonamide in 200 ml of ethanol is treated with 1, 5 ml of hydrazine hydrate, and the mixture is stirred and heated at reflux for six hours. A precipitate forms within an hour. After six hours, 5 ml of HCI are added and the mixture is heated at reflux for one hour, and allowed to stand at room temperature for 18 hours. The precipitate is collected, stirred with 50 ml of hot water, and the insoluble components are washed with 50 ml of water. The combined water washings are evaporated in a vacuum to a dry residue. The residue is dissolved in 100 ml of saturated sodium bicarbonate, treated with activated carbon, filtered, and the filtrate is acidified with acetic acid and concentrated in vacuo to 100 ml. The precipitate is collected, washed with 25 ml of cold water and dried to form a solid, m.p. 200°C. Example 98 4-bromo-N-r3-f4-(methylsulfonylamino)phenoxys1propynebenzamide A 1.6 g sample from Example 97, 4-[4-(methanesulfonylamino)-phenoxypropanamine is dissolved in 50 ml of water and 3 ml of 10 N NaOH. While stirring, a solution of 1.7 g of 4-bromobenzoyl chloride in 100 ml of diethyl ether is added. After stirring for five hours, a precipitate forms, and 2 ml of acetic acid is added. The precipitate is collected, washed with 50 ml of water and air-dried to a residue (A). The filtrate is evaporated with air to a residence (B). The residue A is crystallized from ethanol:water to form 1.1 g of solid, m.p. 208-209°C. The residue B is crystallized from ethanol:water to form 0.4 g of solid, m.p. 208-208°C. Example 99 4- methyl- N-[ 4-[ 4-( 1 H- imidazol- 1- ynphenoxyl- 2- butvn- 1- ylbenzenesulfonamide By following the procedures in examples 30, 31 and 32 and substituting 1,4-dichloro-2-butyne for (E)-1,4-dichloro-2-butene in the procedure according to example 30, the title compound is obtained. Pharmacology 1. Test for prolongation of action potential duration. Description Preparation of heart muscle: Male Hartley guinea pigs (Charles River, NY) weighing between 120 and 160 g are anesthetized intraperitoneally with pentothal. After thoracotomy, the heart is removed and immediately placed in oxygenated (100% 02) Tyrodes-HEPES solution with the following composition: NaCl 140.0 mM, KCl 4.0 mM, MgCl2 1.0 mM, CaCl2 1.8 mM, glucose 10, 0 mM and HEPES pH 7.4, 5.0 mM. Thin (less than 1 mm) papillary muscle is excised from the right ventricle and mounted in a 1.5 ml plexiglass chamber (BSC chamber, MedicalSystems Corp., Greenvale, NY). The chamber is constantly perfused at a rate of 2.5 ml per minute with oxygenated Tyrodes-HEPES solution at a constant temperature of 37°C. Measurements of transmembrane action potentials: The stimulating and recording electronics are composed of Digitimer Neurolog modules (Medical Systems Corp., Greenvale, NY). The isolated papillary muscle is held in place by a bipolar platinum stimulation electrode connected to a Neurolog NL800 Stimulus Isolation Unit. The pair of platinum wires is insulated with Teflon except at the tips, and the distance between the electrodes is less than 1 mm. Electrical stimulation of the muscle is done with pulses of 1 millisecond duration, emitted from a Neurolog NL510 Pulse Buffer according to signals generated by the Neurolog NL304 Period Generator and NL403 Delay-Width units. The stimulus limit is determined during experiments before drug perfusion, and the intensity of the current pulse is set 1.5 times this limit. The preparation is subjected to a pulse of 0.5 Hz for at least one hour for equilibration before the measurements are made. Transmembrane action potentials are recorded intracellularly with 3 M KCl-filled glass capillary microelectrodes (Dagan Corp., Minneapolis, MN), with tip diameter < 1 µm and impedance of 20-50 Megohms. A single fixed playing is maintained throughout the control and drug superfusion periods. A silver-silver chloride electrode in the bath serves as a reference. The signals are amplified with Neurolog NL 102 DC PreAmp and NL106 AC-DC Amplifier and displayed on a Tektronix 5110 oscilloscope. The action potentials are plotted on-line by a Hewlett-Packard 7475-A plotter. The signals are also fed to the DATA 6100 Universal Waveform Analyzer (Data Precision, Danvers, MA) for on-line analysis of action potential waveforms. Experimental timing signals, initialization of the DATA 6100, acquisition of analyzed data from the DATA 6100, and plotting functions are under the control of special software running on an IBM-AT microcomputer. The action potential parameters calculated with DATA 6100 are: maximum upstroke velocity (max dV/dT), action potential amplitude (APA), resting membrane potential (RMP), and action potential duration at 25% (APD25), 50% (APD50), and 90 % (APD90) repolarization. The present series of compounds produced a minimum of 5% increase in prolongation of action potential duration using the test conditions described above. 27 Significance of data Class III antiarrhythmic agents prolong cardiac action potential duration by blocking cardiac potassium channels. This prolongation of action potential duration causes a prolongation of cardiac tissue resistance, namely a delay in tissue recovery from inexcitability. When a renewed impulse encounters tissue that cannot be excited, the impulse is stopped and the arrhythmia disappears. Agents capable of producing this effect would be useful in preventing sudden death from ventricular tachycardia and fibrillation, the most lethal heart disorder that kills nearly half a million Americans each year. Class III antiarrhythmic agents may also be effective against atrial fibrillation, a condition that afflicts millions of older people. A unique feature of this class of compounds is the lack of excessive prolongation of the heart's action potential at slow rhythms. This finding suggests that the compounds would have less pro-arrhythmic tendencies, especially the type known as "Torsades de Pointes". The existing anti-arrhythmic agents have this pro-arrhythmic tendency. As potassium channel blockers, the compounds may find other uses as memory enhancers in Alzheimer's disease, neurotransmitter release in depression and insulin release in diabetes. When the compounds, or where they can be used as a pharmaceutically acceptable salt, are used for the above purposes, they can be combined with one or more pharmaceutically acceptable carriers, for example solvents, diluents and the like, and can be administered orally in such forms as tablets, capsules , dispersible powders, granules or suspensions containing, for example, from about 0.05 to 5% suspending agent, syrups containing, for example, from about 10 to 50% sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations can contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more commonly between about 5% and 60% by weight. The effective dosage of active ingredient used may vary depending on the particular compound used, the mode of administration and the severity of the condition being treated. In general, however, satisfactory results are obtained when the compounds according to the invention are administered in a daily dosage of from about 0.5 to about 500 mg per kg of the animal's body weight, preferably given in divided doses two to four times a day, or in a form with delayed release . For most large animals, the daily dosage will be from about 1 to about 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen can be adjusted to provide the optimal therapeutic response. For example, several divided doses can be administered daily, or the dose can be reduced proportionally according to how critical the therapeutic situation is. These active compounds can be administered orally as well as intravenously, intramuscularly or subcutaneously. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, and kaolin, while liquid carriers include sterile water, polyethylene glycols, nonionic surfactants, and edible oils such as corn, peanut, and sesame oil, as appropriate for the nature of the active ingredient and the particular form of administration that is desired. Adjuvants which are usually used in the preparation of pharmaceutical mixtures can advantageously be included, such as flavoring agents, coloring agents, preservatives and antioxidants, for example vitamin E, ascorbic acid, BHT and BHA. The preferred pharmaceutical mixtures from the point of view of easy preparation and administration are solid mixtures, especially tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred. These active compounds can also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant, such as hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under normal conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile, and must be liquid to such an extent that it can be easily injected. It must be stable under conditions of manufacture and storage, and must be protected against the contaminating effect of micro-organisms such as bacteria and fungi. The carrier can be a solvent or a dispersion medium containing, for example, water, ethanol (for example glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof and vegetable oil. In particular, the anti-arrhythmic compounds of this invention will be therapeutically useful in treatment, and as a viable therapeutic strategy for monitoring ventricular arrhythmia and preventing sudden cardiac death. 1. Compound characterized by the general formula I: in which R1 is R <3> S02 NH- -NO, , - <NH>2 , -CN f -CSNH 2 R<3> is CrC3 straight chain alkyl; X is O, S, SO or SO 2 ; There ner an integer from 3 to 10; k is an integer from 1 to 4; m is an integer from 1 to 4; Yer R <2> is or CrC8 alkyl, straight chain or branched Z,Z <1> and Z <2> are independently selected from H, Cr C4 straight-chain or branched alkyl, -CF3 ,-N02 , -NHCOR <3> : -OR <4> , -CN, Cl, Br, F or I, with the proviso that when R <1> is 1-imidazolyl, X is oxygen, D is -(CH2 )4 -, Y is -COR <2> , and R <2> is and two of Z, Z <1> and Z <2> are H, then the remaining substituent Z, Z <1> , or Z <2> cannot be Cl in the 4-position; R<4> is CrC4 straight or branched alkyl; A is oxygen or a bond; or a pharmaceutically acceptable salt thereof. 2. Compound according to claim 1, characterized in that R<1> is 1-imidazolyl or 1- or 5-tetrazolyl, and Y is SO 2 R 2 . 3. Compound according to claim 2, characterized in that it is 4-(t-butyl)-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide. 4. Compound according to claim 2, characterized in that it is 4-methyl-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide. 5. Compound according to claim 2, characterized in that it is N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-8-quinoline sulfonamide. 6. Compound according to claim 2, characterized in that it is N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-2-thiophenesulfonamide. 7. Compound according to claim 2, characterized in that it is N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-1,2-dihydro-1-methyl-2-oxobenz[cd ]indole-6-sulfofiamide. 8^ Compound according to claim 2, characterized in that it is 4-nitro-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide. 9. Compound according to claim 2, characterized in that it is 4-methoxy-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide. 10. Compound according to claim 2, characterized in that it is 4-butoxy-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide. 11. Compound according to claim 2, characterized in that it is 4-bromo-N-[5-[4-(1H-imidazol-1-yl)phenoxy]pentyl]benzenesulfonamide. 12. Compound according to claim 2, characterized in that it is N-[4-[4-(1H-imidazol-yl)phenoxy]butyl]benzenesulfonamide. 13. Compound according to claim 2, characterized in that it is (E)-4-methyl-N-[4-[4-(1H-imidazol-1-yl)phenoxy]buten-1yl]benzenesulfonamide. 14. Compound according to claim 2, characterized in that it is 4-bromo-N-[4-[4-(1H-tetrazol-1-yl)phenoxy]butyl]benzenesulfonamide. 15. Compound according to claim 2, characterized in that it is 4-methyl-N-[4-[4-(1H-tetrazol-1-yl)phenoxy]butyl]benzenesulfonamide. 16. Compound according to claim 2, characterized in that it is selected from: 4-bromo-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide, 4-Chloro-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide, N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-2-naphthalenesulfonamide, 4-iodo-N-[4-[4-(1H-imidazol-1-yl)phenoxy] butyl]benzenesulfonamide, r\U[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenemethanesulfonamide, 2>-5-dichloro-N-[4-[4-(1H-imidazol-1-yl)phenoxy ]butyl]benzenesulfonamide, 4-trifluoromethyl-N-[4-[4-(1 H-imidazol-1 -yl)phenoxy]butyl]benzenesulfonamide, 4-acetamido-N-[4-[4-(1 H-imidazole -1-yl)phenoxy]butyl]benzenesulfonamide, N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-1-octanesulfonamide, 2,4,6-trimethyl-N-[4-[4-(1H-imidazol-1 -yl)phenoxy]butyl]benzenesulfonamide, N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-2,1,3-benzothiadiazole-4-sulfonamide, 4- cyano-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide, N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzenesulfonamide , N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]-2,1,3-benzoxadiazole-4-sulfonamide, 5-aminomethyl-N-[4-[4-(1H -imidazol-1-yl)phenoxy]butyl]-2-thiophenesulfonamide, N-[5-[4-(1H-imidazol-1-yl)phenoxy]pentyl]hexanesulfonamide, 4-methyl-N-[4-[ 4-(1H-tetrazol-5-yl)phenoxy]butyl]benzenesulfonamide, N-[10-[4-[(1H-tetrazol-1-yl)phenoxy]decyl]]-2-naphthalenesulfonamide, and N-[ 4-[4-(1H-tetrazol-1-yl)phenoxy]butyl]-2,1,3-benzothiadiazole-4-sulfonamide. 17. Compound according to claim 1, characterized in that R is different from 1-imidazolyl or 1- or 5-tetrazolyl and Y is -SO 2 R<2> . 18. Compound according to claim 17, characterized in that it is selected from: 4-methyl-N-[4-(4-nitrophenoxy)butyl]benzenesulfonamide, 4-methyl-N-[4-(4-aminophenoxy)butyl]benzenesulfonamide, 1- [4-[4-(4-bromobenzene-sulfonamido)butoxy]phenyl]ethanone, 4-bromo-N-[4-[4-(pyrimidin-4-yl)phenoxy]butyl]benzenesulfonamide, 4-bromo- N-[4-(4-(1H-pyrazol-3-yl)phenoxy]butyl]benzenesulfonamide, 4-methyl-N-[4-(4-cyanophenyloxy)butyl]benzenesulfonamide, 4-methyl-N-[4- (4-(thiocarbamylphenoxy)butyl]benzenesulfonamide, N-dimethylaminomethylidene-4-[4-(4-methylphenylsulfonamido)butyloxy]-thiobenzamide, 4-methyl-N-[4-[4-[(4-chlorophenyl)thiazol-2-yl]-phenoxy]butyl]benzenesulfonamide, 4-methyl-N-[4-(4-(phenylphenoxy)butyl]benzenesulfonamide, 4-Bromo-N-[4-[(4-phenylcarbonylphenoxy)butyl]benzenesulfonamide, 3Jilor-N-[4-[(4-phenylcarbonylphenoxy)butyl]benzenesulfonamide, 4-T netyl-N-[4-(4-( acetamidophenylthio)butyl]benzenesulfonamide, 4-methyl-N-[4-(4-(aminophenylthio)butyl]benzenesulfonamide, 4-methyl-N-[4-[(4-methanesulfonamidophenyl)thio]butyl]benzenesulfonamide, 4-methyl- N-[4-(4-acetarhidophenylsulfonyl)butyl]benzenesulfonamide, and 4-methyl-N-[4-(pyrrol-1-yl)phenyloxy]butyl]benzenesulfonamide. 19. Compound according to claim 1, characterized in that Y is -COR 2 or PO(A-phenyl) 2 where A is oxygen or a bond. 20. Compound according to claim 19, characterized in that it is selected from: 4-bromo-N-[4-[4-(1H-imidazol-1-ylphenoxy]butyl]benzamide, 2-bromo-N-[4-[4-(1 H-imidazol-1-yl)phenoxy]butyl]benzamide, N-[4-[4-(1 H-imidazol-1-yl)phenoxy]butyl] benzamide, 4-methyl-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzamide, 4-methoxy-N-[4-[4-(1H-imidazol-1-yl)phenoxy ]butyl]benzamide, N-[4-[4-(1 H-imidazol-1-yl)phenoxy]butyl]-1-naphthalenecarboxamide, 4-fluoro-N-[4-[4-(1 H-imidazol-1-yl)phenoxy ]butyl]benzamide, 4-iodo-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzamide, N-(4-bromophenyl)-N'-[4-[4-(1H-imidazol- 1-yl)phenoxy]butyl]urea, 0,0'-diphenyl-N-[4-[4-(1H-imidazol-1-yl)phenyloxy]butyl]phosphoramide, P,P-diphenyl-N-[ 4-[4-(1 H -imidazol-1 -yl)phenoxy]butyl]phosphinamide, 3-bromo-N-[4-[4-(1 H -imidazol-1 -yl)phenoxy]propyl]benzamide 3- bromo-N-[4-[4-(1H-imidazol-1-yl)phenoxy]butyl]benzamide, 3-bromo-N-[4-[4-(1H-imidazol-1-yl)phenoxy]pentyl]benzamide, and 4-bromo-N-[3-[4-[(methylsulfonyl)amino]phenoxy]propyl]benzamide. 21. Pharmaceutical mixture characterized in that it comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula whereR is <1> R <3> SO2 NH- -NO2 , -^2 . R <3> is (Cr C3 ) straight chain lower alkyl; X is O, S, SO or SO 2 ; There ner an integer from 3 to 10; k is an integer from 1 to 4; m is an integer from 1 to 4; Yer R <2> is or Cr C8 alkyl, straight chain or branched Z, Z <1> and Z <2> are independently selected from H, Cr C4 straight chain or branched alkyl, -CF3 ,-NO2 , -NHCOR <3> , -OR <4> , -CN, Cl, Br, F, or I, with the proviso that when R <1> is 1-imidazolyl, X is oxygen, D is -(CH2 )4 -, Y is -COR <2> , and R < 2> is and two of Z, Z <1> and Z <2> are H, then the remaining substituent Z, Z <1> or Z <2> cannot be Cl in the 4-position; R4 is CrC4 straight chain or branched alkyl, A is oxygen or a bond; or a pharmaceutically acceptable salt thereof. 22. Use of a compound of the formula where R <1> is R <3> is (Cr C3 ) straight chain lower alkyl; X is O, S, SO or SO 2 ; There ner an integer from 3 to 10; k eret whole number from 1 to 4; m is an integer from 1 to 4; Yer R <2> is or Cr C8 alkyl, straight chain or branched Z, Z <1> and Z <2> are independently selected from H, Cr C4 straight chain or branched alkyl, -CF3 ,-NO2 , -NHCOR <3> , -OR <4> , -CN, Cl, Br, F, or I with the proviso that when R <1> is 1-imidazolyl, X is oxygen, D is -(CH2 )4 -, Y is -COR <2> , and R <2 > is and two of Z, Z<1> and Z<2> are H, then the remaining substituent Z,Z<1> or Z<2> cannot be Cl in the 4-position; R<4> is Cr C 4 straight or branched alkyl; A is oxygen or a bond; or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical preparation for the treatment of cardiac arrhythmia in a mammal. 23r Process for preparing compounds of the formula in which R is <1> R <3> S02 NH- -N02 , - <NH>2 , -CN t <-> CSNH2 R <3> is (CrC3) straight chain lower alkyl; X is O, S, SO or SO 2 ; There ner an integer from 3 to 10; k is an integer from 1 to 4; m is an integer from 1 to' 4; Yer R <2> is or C<r>C8 alkyl, straight chain or branched Z, Z <1> and Z <2> are independently selected from H, Cr C4 straight chain or branched alkyl, -CF3 , -NO2 , -NHCOR <3> , -OR <4> , -CN, Cl, Br, F , or I, with the proviso that when R <1> is 1-imidazolyl, X is oxygen, D is -(CH2 )4 -, Y is -COR <2> , and R <2> is and two of Z, Z<1> and Z<2> are H, then the remaining substituent Z, Z<1> or Z<2> cannot be Cl in the 4-position; R <4> is CrC4 straight chain or branched alkyl, A is oxygen or bond; characterized by converting a compound with the formula: with a compound of the formula: YCI where R <2> is or Cr C8 alkyl, straight chain or branched to form the compounds of formula I.